filmov
tv
Update from KAITLIN for high-risk HER2-positive early breast cancer
Показать описание
Dr Julia Gralow speaks to ecancer online about her ASCO 2020 virtual presentation which discussed the KAITLIN study.
KAITLIN looked at trastuzumab emtansine (T-DM1) + pertuzumab, vs trastuzumab + pertuzumab + taxane after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
The study did no reach its co-primary endpoints, and Dr Gralow explains why this may be, as well as some of the lessons learnt from the trial.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
KAITLIN looked at trastuzumab emtansine (T-DM1) + pertuzumab, vs trastuzumab + pertuzumab + taxane after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
The study did no reach its co-primary endpoints, and Dr Gralow explains why this may be, as well as some of the lessons learnt from the trial.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
0:03:50
0:00:15
0:19:23
0:01:40
0:02:23
0:06:28
0:02:10
1:00:35
0:33:21
0:09:57
0:01:30
0:22:28
0:00:43
0:01:27
0:12:25
0:00:44
0:04:27
0:00:45
0:01:47
0:02:20
0:00:17
0:21:23
0:00:04
1:00:32